Combination Effective Treating Non Small Cell Lung Cancer
Pegilodecakin (AM0010) with nivolumab (Opdivo) or pembrolizumab (Keytruda) induced an overall response rate in 41% in patients with advanced non–small cell lung cancer, according to findings presented at the 2018 ASCO Annual meeting.
Combining pegilodecakin (AM0010) with nivolumab (Opdivo) or pembrolizumab (Keytruda) induced an overall response rate (ORR) of 41% in patients with advanced non—small cell lung cancer (NSCLC), according to findings from an early phase study presented at the 2018 ASCO Annual meeting.
At a median follow-up of 24.7 months (range, 9.1-39.1), partial responses were observed in 11 of 27 evaluable patients who received pegilodecakin plus a PD-1 inhibitor. An additional 12 patients had stable disease.
The median overall survival (OS) was 32.2 months in the patients who received pegilodecakin/pembrolizumab and the median progression-free survival (PFS) was 11 months. The median OS and PFS have not yet been reached for the cohort of patients receiving pegilodecakin plus nivolumab.
“Pegilodecakin when added to anti—PD-1 therapy in advanced NSCLC patients was associated with response rates and durability of benefit greater than has been seen with anti–PD-1 alone,” lead investigator Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, wrote in their poster.
Click to continue reading on OncLive.
